The Avirmax team’s extensive experience with its unique viral vector system and many years in rAAV-based gene therapy process development, regulatory submissions for early and late clinical phases, at early and late clinical phases, provide our clients with a best-in-class service experience. Avirmax has developed robust processes to provide consistently high titers reaching 1e15 vg/L, in a shortened timeline, allowing clients to obtain quality product quickly.
Avirmax has a full complement of industry professionals with over 85 years of experience in protein drug and gene therapy development from early-stage through to cGMP commercial manufacturing. Our service team is experienced in gene target screening, expression cassette design, codon optimization, and production of large quantities of AAV vectors.